Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Long-Term Investments for 6 consecutive years, with $19.0 million as the latest value for Q3 2025.

  • Quarterly Long-Term Investments changed 0.0% to $19.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $19.0 million through Sep 2025, changed 0.0% year-over-year, with the annual reading at $13.0 million for FY2024, 59.33% down from the prior year.
  • Long-Term Investments hit $19.0 million in Q3 2025 for Lyell Immunopharma, roughly flat from $19.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $283.5 million in Q4 2021 to a low of $10.0 million in Q1 2023.
  • Historically, Long-Term Investments has averaged $50.3 million across 5 years, with a median of $32.0 million in 2023.
  • Biggest five-year swings in Long-Term Investments: surged 254.44% in 2021 and later crashed 84.16% in 2022.
  • Year by year, Long-Term Investments stood at $283.5 million in 2021, then plummeted by 84.16% to $44.9 million in 2022, then fell by 28.73% to $32.0 million in 2023, then tumbled by 59.33% to $13.0 million in 2024, then soared by 46.0% to $19.0 million in 2025.
  • Business Quant data shows Long-Term Investments for LYEL at $19.0 million in Q3 2025, $19.0 million in Q2 2025, and $19.0 million in Q1 2025.